China have a breakthrough therapy process like the USA. This was established in 2020 by the China National Medical Products Administration (NMPA).
Bisantrene solves a problem with unmet clinical need while also improving cancer outcomes for patients. If the human data confirms circumstantial and preclinical evidence, then I think Bisantrene could be a cash generating asset much sooner than expected.
Ann: First Patient Safely Combine Dosed in Phase 1 RC220 Trial, page-147
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.000(0.00%) |
Mkt cap ! $206.7M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.20 | $1.17 | $171.0K | 143.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1575 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 5000 | 1 |
View Market Depth
| Last trade - 14.49pm 07/08/2025 (20 minute delay) ? |
| RAC (ASX) Chart |